STAT August 21, 2025
Two members of Congress and a veteran call to keep momentum going
After decades of underinvestment in new approaches to treating post-traumatic stress disorder and related conditions, the Department of Veterans Affairs is finally turning a corner. In late 2023, the VA announced its first investment in psychedelic research in more than 50 years, launching clinical trials of MDMA-assisted therapy for PTSD. Now, we must keep the momentum going.
This historic decision reflected the growing body of evidence demonstrating the potential of psychedelic-assisted therapies to treat PTSD, depression, alcohol use disorder, and other mental health conditions, many of which disproportionately affect veterans. It also aligns with bipartisan congressional support and evolving policies across federal health agencies, prioritizing evidence-based innovation.
One...
Today's Sponsors
Today's Sponsor